Literature DB >> 22251008

Alternative medicines as emerging therapies for inflammatory bowel diseases.

Udai P Singh1, Narendra P Singh, Brandon Busbee, H Guan, Balwan Singh, Robert L Price, Dennis D Taub, Manoj K Mishra, Mitzi Nagarkatti, Prakash S Nagarkatti.   

Abstract

Inflammatory bowel disease (IBD) can be divided into two major categories, ulcerative colitis (UC) and Crohn disease (CD). While the main cause(s) of IBD remain unknown, a number of interventional and preventive strategies have been proposed for use against CD and UC. Many reports have focused on the use of alternative natural medicines as potential therapeutic interventions in IBD patients with minimal side effects. While the use of alternative medicines may be effective in IBD patients that are refractory to corticosteroids or thiopurins, alternative treatment strategies are limited and require extensive clinical testing before being optimized for use in patients.
Copyright © Informa Healthcare USA, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22251008      PMCID: PMC4138959          DOI: 10.3109/08830185.2011.642909

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  183 in total

1.  The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats.

Authors:  Y Mao; S Nobaek; B Kasravi; D Adawi; U Stenram; G Molin; B Jeppsson
Journal:  Gastroenterology       Date:  1996-08       Impact factor: 22.682

2.  Effects of Boswellia serrata gum resin in patients with ulcerative colitis.

Authors:  I Gupta; A Parihar; P Malhotra; G B Singh; R Lüdtke; H Safayhi; H P Ammon
Journal:  Eur J Med Res       Date:  1997-01       Impact factor: 2.175

Review 3.  Epidemiology of inflammatory bowel disease: an update.

Authors:  M G Russel; R W Stockbrügger
Journal:  Scand J Gastroenterol       Date:  1996-05       Impact factor: 2.423

4.  n-3 fatty acids only delay early relapse of ulcerative colitis in remission.

Authors:  K Loeschke; B Ueberschaer; A Pietsch; E Gruber; K Ewe; B Wiebecke; W Heldwein; R Lorenz
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

5.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.

Authors:  D J Berg; N Davidson; R Kühn; W Müller; S Menon; G Holland; L Thompson-Snipes; M W Leach; D Rennick
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

6.  Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.

Authors:  M Jang; L Cai; G O Udeani; K V Slowing; C F Thomas; C W Beecher; H H Fong; N R Farnsworth; A D Kinghorn; R G Mehta; R C Moon; J M Pezzuto
Journal:  Science       Date:  1997-01-10       Impact factor: 47.728

7.  Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis.

Authors:  A D Millar; D S Rampton; C L Chander; A W Claxson; S Blades; A Coumbe; J Panetta; C J Morris; D R Blake
Journal:  Gut       Date:  1996-09       Impact factor: 23.059

8.  Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis.

Authors:  C J Mulder; P Fockens; J W Meijer; H van der Heide; E H Wiltink; G N Tytgat
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-06       Impact factor: 2.566

9.  Defined-formula diets versus steroids in the treatment of active Crohn's disease: a meta-analysis.

Authors:  A Messori; G Trallori; G D'Albasio; M Milla; G Vannozzi; F Pacini
Journal:  Scand J Gastroenterol       Date:  1996-03       Impact factor: 2.423

10.  Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease.

Authors:  A Belluzzi; C Brignola; M Campieri; A Pera; S Boschi; M Miglioli
Journal:  N Engl J Med       Date:  1996-06-13       Impact factor: 91.245

View more
  7 in total

1.  Arjunarishta alleviates experimental colitis via suppressing proinflammatory cytokine expression, modulating gut microbiota and enhancing antioxidant effect.

Authors:  Damita Cota; Sanjay Mishra; Sushant Shengule
Journal:  Mol Biol Rep       Date:  2020-09-03       Impact factor: 2.316

2.  Effectiveness of C5a aptamers in a TNBS-induced colitis mouse model.

Authors:  Zhiping Li; Xiwen Wang; Man Chen; Yuanyuan Wang; Rui Sun; Han Qu; Yu Sun; Weicun Gao; Bo Li; Xiaolin Dong; Yandong Zhang; Zhiping Xia
Journal:  Exp Ther Med       Date:  2017-10-10       Impact factor: 2.447

Review 3.  Emerging role of protein modification in inflammatory bowel disease.

Authors:  Gaoying Wang; Jintao Yuan; Ji Luo; Dickson Kofi Wiredu Ocansey; Xu Zhang; Hui Qian; Wenrong Xu; Fei Mao
Journal:  J Zhejiang Univ Sci B       Date:  2022-03-15       Impact factor: 3.066

4.  Role of microRNAs in resveratrol-mediated mitigation of colitis-associated tumorigenesis in Apc(Min/+) mice.

Authors:  Ibrahim Altamemi; E Angela Murphy; James F Catroppo; Elizabeth E Zumbrun; Jiajia Zhang; Jamie L McClellan; Udai P Singh; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2014-05-09       Impact factor: 4.030

Review 5.  Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view.

Authors:  Mi-Kyung Sung; Mi-Young Park
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

Review 6.  Nutraceuticals and Diet Supplements in Crohn's Disease: A General Overview of the Most Promising Approaches in the Clinic.

Authors:  Barbara De Conno; Marcella Pesce; Martina Chiurazzi; Marta Andreozzi; Sara Rurgo; Chiara Corpetti; Luisa Seguella; Alessandro Del Re; Irene Palenca; Giuseppe Esposito; Giovanni Sarnelli
Journal:  Foods       Date:  2022-04-04

Review 7.  Resveratrol Role in Autoimmune Disease-A Mini-Review.

Authors:  Ana Lígia de Brito Oliveira; Valter Vinicius Silva Monteiro; Kely Campos Navegantes-Lima; Jordano Ferreira Reis; Rafaelli de Souza Gomes; Dávila Valentina Silva Rodrigues; Silvia Letícia de França Gaspar; Marta Chagas Monteiro
Journal:  Nutrients       Date:  2017-12-01       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.